Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sarepta Therapeutics, a US-based developer of RNA-based therapeutics, has agreed to acquire a multifunctional manufacturing facility on 26 acres of land in Massachusetts, US.
Subscribe to our email newsletter
The company intends to use the facility to manufacture investigational exon skipping therapies for Duchenne muscular dystrophy (DMD).
The transaction, which includes about $25m in acquisition costs and planned improvements, is expected to be completed in July subject to conditions and extensions in the agreement.
Sarepta Therapeutics president and chief executive officer Chris Garabedian said the strategic acquisition complements the company’s existing internal manufacturing capability and global network of suppliers.
"While we scale up to address the potential U.S. commercial demand for our lead product candidate eteplirsen in the event of an approval next year, the addition of internal resources will enhance our ability to advance the development of our broader exon skipping platform and explore the potential of our technology platform in other therapeutic areas," Garabedian said.
The company is focused in the development of phosphorodiamidate morpholino oligomer (PMO) chemistries for RNA therapeutics.
The facility will be used to further improve and scale the company’s manufacturing processes for PMO chemistries.
Additionally, the facility will be used to manufacture drug supply to support clinical trials of the company’s exon skipping therapies for DMD, as well as research and development of future potential products and modified PMO chemistries.